SCHEMBL22284358

SCHEMBL22284358

CC(C)(C)OC(=O)N1CCC(C(=O)CCCOCc2ccccc2)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STS P08842 1/20 0.56
SMN1; SMN2 Q16637 4/20 0.50
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
GPR119 Q8TDV5 2/20 0.50
HTT P42858 1/20 0.49
KDM4E B2RXH2 1/20 0.48
PKM P14618 1/20 0.48
CYP2C19 P33261 1/20 0.48
ABL1 P00519 1/20 0.47
RIN1 Q13671 1/20 0.47
PTPRB P23467 1/20 0.47
PTPN11 Q06124 1/20 0.47
PTPN2 P17706 1/20 0.46
PTPN1 P18031 1/20 0.46
PTPN6 P29350 1/20 0.46
KEAP1 Q14145 1/20 0.46
NFE2L2 Q16236 1/20 0.46
GAA P10253 1/20 0.46
THRB P10828 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22284332 0.90 STS (0.55) STSSMN1; SMN2NPC1RAB9AGPR119
SCHEMBL3251863 0.84 KDM4E (0.58) STSSMN1; SMN2GPR119KDM4EPKM
SCHEMBL22284434 0.83 STS (0.50) STSSMN1; SMN2NPC1RAB9AGPR119
SCHEMBL13096781 0.83 STS (0.52) STSSMN1; SMN2NPC1RAB9AGPR119
SCHEMBL31303428 0.83 STS (0.52) STSSMN1; SMN2NPC1RAB9AGPR119
SCHEMBL31511550 0.83 STS (0.54) STSSMN1; SMN2NPC1RAB9AGPR119
SCHEMBL20133355 0.82 STS (0.51) STSSMN1; SMN2NPC1RAB9AGPR119
SCHEMBL4117740 0.82 STS (0.64) STSSMN1; SMN2NPC1RAB9AGPR119
SCHEMBL21458596 0.82 STS (0.53) STSSMN1; SMN2NPC1RAB9AGPR119
SCHEMBL27378608 0.82 KDM4E (0.56) STSSMN1; SMN2GPR119KDM4EPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3526196-B1 ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS MERCK SHARP & DOHME LLC (US) 2026-03-18 EP disclosed
US-11655216-B2 Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use MERCK SHARP & DOHME LLC (US) 2023-05-23 US disclosed
US-20200247754-A1 ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE MERCK SHARP & DOHME CORP. (US) 2020-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200247754-A1 ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE NR1H2, NR1H3, NR1H4 STS 1202/4885SMN1; SMN2 3985/4885NPC1 117/4885
US-11655216-B2 Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use NR1H2, NR1H3, NR1H4 STS 1202/4885SMN1; SMN2 3985/4885NPC1 117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.